Aytekin Mahmut Nedim, Öztürk Recep, Amer Kamil
Department of Orthopedics and Traumatology, Ankara Yildirim Beyazit University, Ankara, Turkey.
Department of Orthopedics and Traumatology, Dr Abdurrahman Yurtaslan Oncology Training and Research Hospital, Ankara 06200, Turkey.
J Oncol. 2020 Jun 16;2020:2809647. doi: 10.1155/2020/2809647. eCollection 2020.
Adamantinomas are rare low-grade malignant bone tumors. This study aims to describe the demographic characteristics and survival rates of patients suffering from adamantinomas.
The National Institute of Cancer Surveillance, Epidemiology, and Recent Results (SEER) database was used, and patients diagnosed with adamantinoma between 1973 and 2016 were screened. Patients were classified according to sex, age, race/ethnicity, and marital status, and also tumors were classified according to year of diagnosis, laterality, type of treatment, and follow-up.
The mean age of patients was 30.8 ± 16.7 (range: 4-75). A total of 92 patients were identified; of these, 43 were females and 49 were males. The mean follow-up period was 138.1 ± 90.3 (range: 1-156) months. Mean survival duration was 287.8 ± 15.4 (95% CI: 257.7-317.9) months. Five- and ten-year survival rates were 98.8% and 91.5%, respectively. Besides, survival time was also observed to be independent of gender, age groups, race, marital status, tumor location, and year of diagnosis.
Adamantinoma is a very rare bone tumor that affects the long bones in lower extremities and is more common in men. Five- and 10-year survival prognoses are reasonably satisfactory. Also, survival time is independent of variables such as gender, age, and tumor location.
成釉细胞瘤是一种罕见的低度恶性骨肿瘤。本研究旨在描述成釉细胞瘤患者的人口统计学特征和生存率。
使用美国国立癌症研究所的监测、流行病学和最终结果(SEER)数据库,筛选出1973年至2016年间诊断为成釉细胞瘤的患者。患者按性别、年龄、种族/民族和婚姻状况进行分类,肿瘤也按诊断年份、病变侧、治疗类型和随访情况进行分类。
患者的平均年龄为30.8±16.7岁(范围:4 - 75岁)。共识别出92例患者;其中,女性43例,男性49例。平均随访期为138.1±90.3个月(范围:1 - 156个月)。平均生存时间为287.8±15.4个月(95%置信区间:257.7 - 317.9个月)。5年和10年生存率分别为98.8%和91.5%。此外,还观察到生存时间与性别、年龄组、种族、婚姻状况、肿瘤位置和诊断年份无关。
成釉细胞瘤是一种非常罕见的骨肿瘤,影响下肢长骨,男性更为常见。5年和10年生存预后相当令人满意。而且,生存时间与性别、年龄和肿瘤位置等变量无关。